Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...
In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...
Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...
A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...
Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, ...
SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Positive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis Trial ...
Takeda reports positive Phase 3 data for psoriasis drug zasocitinib, beating placebo and Otezla, with rapid PASI responses ...
A new study published in the Journal of American Medical Association showed that psoriasis patients who used antibiotics had ...
Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial ...
The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...
Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...
People with psoriasis often describe an itchy sensation that burns and is painful. Most people with psoriasis experience itchiness, but there are ways to manage this symptom. People with psoriasis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback